Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

Graceway Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Warts

Treatments: Drug: Resiquimod

Study type: Interventional

Funder types: Industry

Identifiers

NCT00116675

1535-RESI

Details and patient eligibility

About

The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks.

A second purpose is to evaluate the safety of the drug.

Sex: All

Ages: 3 to 11 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of common warts
• Ages between 3 to 11

Exclusion criteria

• Other types of wart(s), ie. plantar
• Currently participating in another clinical study
• Chronic viral hepatitis B or C

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: Single Blind